Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Income from Continuing Operations (2016 - 2025)

Cytokinetics (CYTK) has disclosed Income from Continuing Operations for 16 consecutive years, with 231866000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations changed N/A to 231866000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 688195000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 657837000.0 for FY2025, 14.62% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 231866000.0 at Cytokinetics, down from 178108000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 13681000.0 in Q2 2022, with the low at 231866000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 115002421.05, with a median of 129401000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations tumbled 6173.01% in 2021, then soared 76.76% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 25922000.0 in 2021, then tumbled by 417.27% to 134087000.0 in 2022, then decreased by 0.37% to 134582000.0 in 2023, then dropped by 11.25% to 149729000.0 in 2024, then crashed by 54.86% to 231866000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 231866000.0, 178108000.0, and 122590000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.